Genomic Heterogeneity of Pancreatic Ductal Adenocarcinoma and Its Clinical Impact
Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer death due to limited advances in recent years in early diagnosis and personalized therapy capable of overcoming tumor resistance to chemotherapy. In the last decades, significant advances have been achieved in the identif...
Main Authors: | María Laura Gutiérrez, Luis Muñoz-Bellvís, Alberto Orfao |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/17/4451 |
Similar Items
-
The role of miRNAs in the diagnosis, chemoresistance, and prognosis of pancreatic ductal adenocarcinoma
by: Ren L, et al.
Published: (2018-01-01) -
Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes
by: Lan Zhao, et al.
Published: (2018-05-01) -
Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma
by: Yexin Tong, et al.
Published: (2022-11-01) -
Recent advances in precision medicine for pancreatic ductal adenocarcinoma
by: Hiromitsu Hayashi, et al.
Published: (2021-07-01) -
Current and Future Therapies for Pancreatic Ductal Adenocarcinoma
by: Áine Sally, et al.
Published: (2022-05-01)